Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation

Current Medical Research and Opinion

Volumn 30, Issue 12, 2014, Pages 2461-2469

  Nelson, Winnie W ^a   Song, Xue ^b   Coleman, Craig I ^c   Thomson, Erin ^b   Smith, David M ^b   Damaraju, C V ^a   Schein, Jeffrey R ^a  

^a Health Economics and Outcomes Research Janssen Scientific Affairs   (United States)

^b IBM WATSON HEALTH   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Non valvular atrial fibrillation; Persistence; Rivaroxaban; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; MORPHOLINE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE; WARFARIN;

AGED; ATRIAL FIBRILLATION; COHORT ANALYSIS; COMPARATIVE STUDY; COMPLICATION; FACTUAL DATABASE; FEMALE; HUMAN; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STROKE; UNITED STATES;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MORPHOLINES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STROKE; THIOPHENES; UNITED STATES; WARFARIN;

EID: 84914169119     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.933577     Document Type: Article

References (23)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983-8
2. January CT, Wann LS, Alpert JS, et al. 2014. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. Circulation 2007;115:2689-96
3. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96
4. De Schryver E, van Gijn J, Kappelle L, et al. Nonadherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol 2005;252:1316-21
5. Coleman CI, Coleman SM, Vanderpoel J, et al. Patient satisfaction with warfarin- and non-warfarin-containing thromboprophylaxis regimens for atrial fibrillation. J Investig Med 2013;61:878-81
6. Suh DC, Choi JC, Schein J, et al. Factors associated with warfarin discontinuation, including bleeding patterns, in atrial fibrillation patients. Curr Med Res Opin 2013;29:761-71
7. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987;147:1561-4
8. Wanat MA. Novel oral anticoagulants: a review of new agents. Postgrad Med 2013;125:103-14
9. Capodanno D, Capranzano P, Giacchi G, et al. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. Int J Cardiol 2013;167:1237-41
10. von Elm E, Altman DG, Egger M, et al; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806-8
11. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70
12. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarinassociated hemorrhage. The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011;58:395-401
13. Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011;57:173-80
14. Cohen J. Statistical power analysis for the behavioral sciences, 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988:20-7
15. Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001;54:387-98
16. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput 2009;38:1228-34
17. Evers T, Diamantopoulos A. Real-life treatment persistence with newer oral anticoagulants and potential strokes avoided in patients with atrial fibrillation. Eur Heart J 2013;34(S1):94-95
18. Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999;160:41-6
19. Bourgault C, Sénécal M, Brisson M, et al. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population- based study. J Hum Hypertens 2005;19:607-13
20. Selmer R, Blix HS, Landmark K, et al. Choice of initial antihypertensive drugs and persistence of drug use - a 4-year follow-up of 78,453 incident users. Eur J Clin Pharmacol 2012;68:1435-42
21. Chernew M, Gibson TB, Yu-Isenberg K, et al. Effects of increased patient cost sharing on socioeconomic disparities in health care. J Gen Intern Med 2008;23:1131-6
22. Gibson TB, Song X, Alemayehu B, et al. Cost-sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care 2010;16: 589-600
23. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care 2005;11:730-40